See more : TIE Kinetix N.V. (TIE.AS) Income Statement Analysis – Financial Results
Complete financial analysis of Mace Security International, Inc. (MACE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Mace Security International, Inc., a leading company in the Security & Protection Services industry within the Industrials sector.
You may be interested
- Global Longlife Hospital and R (GLHRL.BO) Income Statement Analysis – Financial Results
- Generation Asia I Acquisition Limited (GAQ) Income Statement Analysis – Financial Results
- Sinomine Resource Group Co., Ltd. (002738.SZ) Income Statement Analysis – Financial Results
- Demant A/S (DEMANT.CO) Income Statement Analysis – Financial Results
- Build Acquisition Corp. (BGSX-WT) Income Statement Analysis – Financial Results
Mace Security International, Inc. (MACE)
About Mace Security International, Inc.
Mace Security International, Inc. designs, manufactures, and sells personal safety and security products to retailers, distributors, and individual consumers worldwide. The company offers pepper sprays, gels, and guns, as well as animal deterrent sprays; personal alarms; stun guns; and combo kits under the Mace brand, as well as self defense products for women. It also sells tactical spray products and systems to law enforcement, security professionals, correctional institutions, and military markets. The company distributes and supports its branded products and services through mass market retailers, wholesale distributors, independent dealers, e-commerce marketers, and installation service providers, as well as Mace.com website. Mace Security International, Inc. was founded in 1965 and is headquartered in Cleveland, Ohio.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.60M | 8.76M | 13.07M | 15.39M | 10.50M | 11.49M | 9.98M | 9.05M | 7.15M | 6.28M | 8.02M | 12.98M | 13.86M | 18.40M | 28.25M | 50.86M | 47.09M | 49.22M | 68.24M | 57.65M | 49.00M | 46.68M | 48.22M | 48.00M | 28.70M | 2.40M | 9.80M | 10.80M | 12.70M | 12.60M | 9.60M |
| Cost of Revenue | 4.85M | 5.42M | 8.01M | 9.20M | 6.58M | 7.13M | 5.58M | 5.37M | 4.39M | 3.97M | 4.93M | 8.08M | 8.95M | 12.87M | 19.94M | 36.27M | 36.55M | 37.91M | 49.78M | 42.05M | 35.81M | 33.21M | 34.10M | 35.12M | 18.50M | 700.00K | 6.30M | 5.90M | 7.10M | 5.90M | 3.30M |
| Gross Profit | 1.75M | 3.34M | 5.06M | 6.20M | 3.93M | 4.36M | 4.40M | 3.69M | 2.76M | 2.31M | 3.09M | 4.90M | 4.91M | 5.52M | 8.31M | 14.59M | 10.54M | 11.30M | 18.46M | 15.60M | 13.18M | 13.48M | 14.13M | 12.89M | 10.20M | 1.70M | 3.50M | 4.90M | 5.60M | 6.70M | 6.30M |
| Gross Profit Ratio | 26.52% | 38.15% | 38.69% | 40.26% | 37.37% | 37.91% | 44.10% | 40.70% | 38.56% | 36.82% | 38.50% | 37.74% | 35.42% | 30.01% | 29.40% | 28.68% | 22.38% | 22.96% | 27.06% | 27.06% | 26.91% | 28.87% | 29.29% | 26.84% | 35.54% | 70.83% | 35.71% | 45.37% | 44.09% | 53.17% | 65.63% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.26M | 4.76M | 4.75M | 4.11M | 5.06M | 4.75M | 4.12M | 3.72M | 3.84M | 4.16M | 6.34M | 7.38M | 8.63M | 9.57M | 15.07M | 20.64M | 18.34M | 16.87M | 15.05M | 12.64M | 9.49M | 8.50M | 7.37M | 7.30M | 6.70M | 1.70M | 4.50M | 4.50M | 5.70M | 6.60M | 5.10M |
| Other Expenses | 1.77M | 260.00K | 294.00K | 357.00K | 455.00K | -1.00K | 362.00K | 155.00K | 140.00K | 0.00 | 0.00 | 0.00 | 514.00K | 582.00K | 790.00K | 1.28M | 2.06M | 1.77M | 4.88M | 10.73M | 5.76M | 3.18M | 2.95M | 2.47M | 1.10M | 500.00K | 700.00K | 700.00K | 700.00K | 500.00K | 200.00K |
| Operating Expenses | 6.02M | 5.02M | 5.05M | 4.47M | 5.51M | 6.28M | 4.48M | 3.87M | 3.98M | 4.26M | 6.51M | 7.96M | 9.14M | 10.15M | 15.86M | 21.92M | 20.40M | 18.64M | 19.94M | 23.38M | 15.24M | 11.67M | 10.31M | 9.77M | 7.80M | 2.20M | 5.20M | 5.20M | 6.40M | 7.10M | 5.30M |
| Cost & Expenses | 10.87M | 10.44M | 13.06M | 13.66M | 12.09M | 13.41M | 10.06M | 9.24M | 8.37M | 8.22M | 11.44M | 16.04M | 18.09M | 23.02M | 35.80M | 58.19M | 56.95M | 56.55M | 69.72M | 65.43M | 51.05M | 44.88M | 44.41M | 44.89M | 26.30M | 2.90M | 11.50M | 11.10M | 13.50M | 13.00M | 8.60M |
| Interest Income | 0.00 | 71.00K | 25.00K | 42.00K | 4.00K | 85.00K | 96.00K | 136.00K | 179.00K | 10.00K | 161.00K | 207.00K | 1.00K | 14.00K | 44.00K | 308.00K | 456.00K | 185.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 212.00K | 71.00K | 25.00K | 42.00K | 57.00K | 43.00K | 45.00K | 48.00K | 51.00K | 0.00 | 0.00 | 0.00 | 405.00K | 65.00K | 51.00K | 410.00K | 450.00K | 1.15M | 1.79M | 1.89M | 1.96M | 2.22M | 2.89M | 3.01M | 4.30M | 100.00K | 0.00 | 100.00K | 100.00K | 100.00K | 200.00K |
| Depreciation & Amortization | 686.00K | 695.00K | 679.00K | 711.00K | 651.00K | 463.00K | 362.00K | 155.00K | 140.00K | 138.00K | 161.00K | 514.00K | 514.00K | 583.00K | 790.00K | 1.28M | 1.46M | 1.62M | 2.35M | 2.51M | 1.96M | 1.95M | 2.81M | 2.47M | 1.10M | 500.00K | 700.00K | 700.00K | 700.00K | 500.00K | 200.00K |
| EBITDA | -3.53M | -972.00K | 1.35M | 2.46M | -989.00K | -1.44M | 282.00K | 83.00K | -629.00K | -1.85M | -3.25M | -2.53M | -3.68M | -8.95M | -7.31M | -12.03M | -6.93M | -6.51M | -854.00K | -5.06M | -100.00K | 3.76M | 6.63M | 5.58M | 3.50M | 1.30M | 0.00 | 400.00K | -100.00K | 100.00K | 1.20M |
| EBITDA Ratio | -53.54% | -11.10% | 5.49% | 15.96% | -8.89% | -11.99% | 3.79% | 1.13% | -12.65% | -29.46% | -40.52% | -19.47% | -26.85% | -21.92% | -23.78% | -11.30% | -18.74% | -13.53% | 3.99% | 4.76% | 6.65% | 9.96% | 12.95% | 12.28% | 23.34% | -16.67% | -11.22% | 2.78% | -2.36% | 0.79% | 12.50% |
| Operating Income | -4.27M | -1.68M | 39.00K | 1.73M | -1.59M | -593.00K | 94.00K | -189.00K | -1.22M | -1.99M | -3.41M | -3.04M | -4.27M | -9.72M | -9.01M | -12.78M | -9.86M | -7.34M | -1.47M | -7.83M | -2.06M | 1.80M | 3.81M | 3.12M | 2.40M | -500.00K | -1.70M | -300.00K | -800.00K | -400.00K | 1.00M |
| Operating Income Ratio | -64.81% | -19.17% | 0.30% | 11.25% | -15.11% | -5.16% | 0.94% | -2.09% | -17.12% | -31.66% | -42.53% | -23.43% | -30.82% | -52.86% | -31.91% | -25.14% | -20.95% | -14.91% | -2.16% | -13.58% | -4.20% | 3.86% | 7.91% | 6.49% | 8.36% | -20.83% | -17.35% | -2.78% | -6.30% | -3.17% | 10.42% |
| Total Other Income/Expenses | -155.00K | -59.00K | 636.00K | -27.00K | -74.00K | -1.35M | -135.00K | 69.00K | 403.00K | -117.00K | -170.00K | -222.00K | -330.00K | -5.71M | -7.00K | -1.96M | 35.00K | 927.00K | -2.05M | -688.00K | -1.53M | -1.89M | -2.37M | -3.32M | -4.30M | -600.00K | 700.00K | 100.00K | 200.00K | -100.00K | 0.00 |
| Income Before Tax | -4.43M | -1.74M | 647.00K | 1.70M | -1.70M | -1.94M | -41.00K | -120.00K | -820.00K | -1.93M | -3.58M | -3.26M | -4.60M | -9.77M | -9.13M | -15.05M | -9.27M | -7.21M | -2.58M | -9.45M | -3.58M | -89.00K | 1.44M | -206.92K | -1.90M | -100.00K | -1.60M | -200.00K | -600.00K | -500.00K | 0.00 |
| Income Before Tax Ratio | -67.16% | -19.84% | 4.95% | 11.07% | -16.16% | -16.92% | -0.41% | -1.33% | -11.48% | -30.80% | -44.65% | -25.14% | -33.20% | -53.11% | -32.32% | -29.58% | -19.68% | -14.64% | -3.78% | -16.40% | -7.31% | -0.19% | 2.99% | -0.43% | -6.62% | -4.17% | -16.33% | -1.85% | -4.72% | -3.97% | 0.00% |
| Income Tax Expense | 2.00K | 59.00K | 8.00K | 3.00K | 3.00K | 2.00K | 2.00K | -19.00K | 1.00K | 1.00K | 1.00K | 19.00K | -80.00K | 30.00K | 3.40M | 100.00K | 98.00K | 156.00K | 2.44M | -3.04M | -50.00K | -32.00K | 534.00K | -66.00K | -600.00K | 400.00K | 0.00 | -100.00K | -200.00K | 100.00K | 200.00K |
| Net Income | -4.43M | -1.80M | 639.00K | 1.70M | -1.70M | -1.95M | -65.00K | 250.00K | -1.03M | -1.94M | -3.58M | -3.28M | -5.14M | -18.10M | -10.95M | -10.65M | -6.59M | -6.78M | -5.02M | -6.41M | -3.53M | -5.79M | 907.63K | 177.14K | -1.30M | -900.00K | -1.70M | -300.00K | -600.00K | -600.00K | 800.00K |
| Net Income Ratio | -67.19% | -20.52% | 4.89% | 11.05% | -16.18% | -16.94% | -0.65% | 2.76% | -14.37% | -30.81% | -44.66% | -25.28% | -37.10% | -98.39% | -38.77% | -20.95% | -13.98% | -13.78% | -7.36% | -11.12% | -7.21% | -12.40% | 1.88% | 0.37% | -4.53% | -37.50% | -17.35% | -2.78% | -4.72% | -4.76% | 8.33% |
| EPS | -0.07 | -0.03 | 0.01 | 0.03 | -0.03 | -0.03 | 0.00 | 0.01 | -0.02 | -0.03 | -0.06 | -0.06 | -0.15 | -1.15 | -0.68 | -0.65 | -0.42 | -0.44 | -0.33 | -0.47 | -0.28 | -0.46 | 0.07 | 0.02 | -0.20 | -0.22 | -0.48 | -0.08 | -0.18 | -0.16 | 0.34 |
| EPS Diluted | -0.07 | -0.03 | 0.01 | 0.03 | -0.03 | -0.03 | 0.00 | 0.00 | -0.02 | -0.03 | -0.06 | -0.06 | -0.15 | -1.15 | -0.68 | -0.65 | -0.42 | -0.44 | -0.33 | -0.47 | -0.28 | -0.46 | 0.07 | 0.02 | -0.20 | -0.22 | -0.48 | -0.08 | -0.18 | -0.16 | 0.34 |
| Weighted Avg Shares Out | 63.30M | 64.88M | 64.51M | 63.83M | 63.23M | 62.96M | 61.80M | 60.50M | 59.20M | 59.02M | 58.93M | 58.95M | 33.64M | 15.75M | 16.20M | 16.46M | 15.81M | 15.27M | 15.27M | 13.68M | 12.41M | 12.63M | 12.72M | 12.24M | 6.58M | 4.17M | 3.54M | 3.75M | 3.33M | 3.75M | 2.35M |
| Weighted Avg Shares Out (Dil) | 65.37M | 64.88M | 64.94M | 63.93M | 63.23M | 63.05M | 62.90M | 61.44M | 59.20M | 59.02M | 58.93M | 58.95M | 33.64M | 15.75M | 16.20M | 16.46M | 15.81M | 15.27M | 15.27M | 13.68M | 12.41M | 12.63M | 12.74M | 12.24M | 6.58M | 4.18M | 3.54M | 3.75M | 3.33M | 3.75M | 2.35M |
Mace Reports Fourth Quarter and Full-Year 2015 Operating Results
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc. (OTCPINK: MACE) today announced operating financial results for the fourth quarter and twelve-month period ended December 31, 2015. (Note: Mace will release full year-end financial statements upon the resolution of a valuation issue related to...
Mace Reports Third Quarter 2015 Financial Results
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc. (OTCPINK: MACE) today announced unaudited financial results for the third quarter and nine-month period ended September 30, 2015. As a result of the timing of customer shipments, which will we be recognized in the fourth...
Mace Reports Second Quarter 2015 Financial Results
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc., (OTCPINK: MACE) today announced unaudited financial results (amounts in thousands) for the second quarter ended June 30, 2015. Second Quarter 2015 Financial Highlights Compared to Prior Year: Net revenue increased 23%. Gross profit increased 63%....
Mace Reports First Quarter 2015 Financial Results
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc., (OTCPINK: MACE) today announced unaudited financial results (amounts in thousands) for the first quarter ended March 31, 2015. The Company reported a $611 or 77% improvement in net income on a $144 or 8.6% increase...
Mace Reports Q4 Gross Profit Increase of 34% & Expense Reduction of 39% in Audited Financial Results For Q4 and Year Ended December 31, 2014
CLEVELAND--(BUSINESS WIRE)--Mace Security International, Inc., (OTCPINK: MACE) today announced audited financial results (all amounts in thousands) for the fourth quarter and year ended December 31, 2014, reflecting a $924 and $1,475 improvement in income from continuing operations compared to prior...
Genzyme and Isis Present KYNAMRO® Clinical Data at the American Heart Association
CAMBRIDGE, Mass. & CARLSBAD, Calif.--(BUSINESS WIRE)--Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. (NASDAQ: ISIS), today announced that new two-year data from a phase 3 long-term extension study of KYNAMRO® (mipomersen sodium) injection was presented at a scientific session at...
Mace® Reports Unaudited Financial Results for the Third Quarter Ended September 30, 2014
CLEVELAND--(BUSINESS WIRE)--Mace Security International, Inc. (OTCPINK: MACE) today announced unaudited financial results for the third quarter ended September 30, 2014. Financial Results, Third Quarter Ended September 30, 2014 and 2013 Net sales for the third quarter of 2014 experienced a...
Mace® Reports Unaudited Financial Results for the Second Quarter Ended June 30, 2014
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc., (OTCPINK: MACE) today announced unaudited financial results for the second quarter ended June 30, 2014. Financial Results, Second Quarter Ended June 30, 2014 and 2013 Net sales for the second quarter of 2014 experienced a...
Mace® Reports Consolidated Financial Statements and Report of Independent Certified Public Accountants, December 31, 2013 and 2012
CLEVELAND--(BUSINESS WIRE)--Mace Security International Inc., (OTCPINK: MACE) today announced audited financial results for the fourth quarter and year ended December 31, 2013 and unaudited results for the first quarter ended March 31, 2014. Fourth quarter and year end audited results...
Source: https://incomestatements.info
Category: Stock Reports